Abivax completes round trip after UC malignancy scare

Abivax shares completed a round trip after an expanded Phase III safety analysis in ulcerative colitis helped reassure investors that earlier malignancy cases were not emerging as a clear drug-related signal. Abivax was the week’s only big gainer on clinical data, while Evommune posted the biggest loss after a Phase IIb miss and program discontinuation in chronic spontaneous urticaria.

Less than a month after  Abivax S.A. (Euronext:ABVX; NASDAQ:ABVX) reported ulcerative colitis (UC) data that spooked investors and sent its shares down 44%, an expanded safety readout from the Phase III ABTECT maintenance trial helped allay those concerns by showing malignancy rates broadly consistent with background rates in UC patients treated with immunosuppressants...